Ultragenyx Pharma (RARE) Misses Q3 EPS by 16c
Tweet
Share
E-mailGet Alerts RARE Hot Sheet
Join SI Premium – FREE
Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.03), $0.16 worse than the analyst estimate of ($0.87).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Netflix climbs following Ackman stake, up 1.8%
- Aebi Schmidt Holding AG (AEBI) Reports Q2 results; offers guidance
- Wolverine World Wide (WWW) Tops Q2 EPS by 2c; offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
